Research By FDA Scientists Faces Fiscal Setback
Agreement on industry user fees may force the agency to scale back its intramural program, which critics say is fragmented. Intramural research at the United States Food and Drug Administration (FDA) is coming under increasing financial pressure and criticism. In discussions with FDA officials, pharmaceutical manufacturers have won an agreement that the user fees they pay will soon no longer help fund the agency's research. Since 1992, approximately $10 million annually from industry user fees
Jul 6, 1997
Agreement on industry user fees may force the agency to scale back its intramural program, which critics say is fragmented. |
![]() CORPORATE BENEFIT: FDA’s Bernard A. Schwetz contends that the agency’s research program provides direct advantages to industry. |
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?